Common joint supplement tied to quicker dementia transition
A large review of health records found that people taking glucosamine were about 25% more likely to see mild cognitive impairment advance to dementia. Experiments with human brain tissue and mouse models hint that the supplement may worsen an unusual sugar-modification process seen in Alzheimer’s disease. The authors caution that only clinical trials can show whether glucosamine actually causes harm.
The study drew on deidentified University of Florida Health records from 2012 through 2024, using artificial intelligence to examine patients diagnosed with mild cognitive impairment or Alzheimer’s disease and related dementias. In both groups, 8% reported glucosamine use, including 2,750 people with MCI and 1,896 with ADRD.
After adjusting for age, sex, and demographics, researchers found a 25% higher likelihood of MCI progressing to dementia among glucosamine users. In the ADRD group, use was also tied to a 25% higher mortality risk, though that pattern did not appear in the MCI group. Lab work involving human brain tissue and mouse models suggested possible effects on an abnormal sugar-tagging process.
The findings could affect millions of older adults who use glucosamine for joint discomfort, especially those with mild cognitive impairment or dementia. Clinicians and families may reconsider routine supplement use, though the evidence remains observational. If confirmed, the results could influence counseling, research priorities, and how patients weigh perceived joint benefits against uncertain neurological risks. Until trials clarify causation, the impact may be caution rather than definitive guidance.